

**For Immediate Release
6 December 2004**

Definiens and BioImage Announce Collaboration for High-Content Screening (HCS) Applications

Munich/Germany and Copenhagen/Denmark , 6 December, 2004 - Definiens, a leading provider of advanced image analysis solutions, and BioImage, a leading drug discovery and assay services company announced today a worldwide, non-exclusive co-development and marketing agreement to deliver tailored applications to the high-content screening (HCS) market.

Definiens' and BioImage's offerings are complementary, whereby BioImage is providing cell-based pathway screening assays with its unique Redistribution® technology, and Definiens is providing Definiens Cellenger®, their unique software for automated image analysis, based on Cognition Technology.

The agreement also includes co-development efforts, combining BioImage's high content assay expertise with Definiens' unique image analysis solution, aiming at the development of specific applications in the area of HCS. This powerful combination enables customers to perform robust data extraction from high content cell-based assays with a flexibility and a throughput not previously available.

BioImage's Redistribution® technology aims at discovering new generations of small molecule drugs that change the activity of signalling pathways by modulating protein translocation. In addition to drug targets such as kinases, Redistribution® assays address disease targets that are not amenable to traditional drug discovery. BioImage performs pathway screens involving protein translocation read-outs using their high content Redistribution® platform. BioImage uses Definiens Cellenger® to measure and quantify the activity of small molecules in Redistribution assays.

The Definiens Cellenger® HCS solution is an advanced software system for the powerful automated high-content analysis of cell-based assays that enable the reliable and fully automated data extraction. The Cellenger® HCS solution allows detailed analysis of structures of interest even in complex image data and the extracted objects are counted and morphometrically measured.

"Our partnership with BioImage brings important benefits to our customers," said Thomas Heydler, CEO of Definiens AG. "With our leading-edge Cellenger HCS solution we offer a comprehensive application for automated image analysis in the HCS marketplace. Now, with the support of BioImage's expertise in developing specific applications for high-content screening, we provide even more sophisticated capabilities. Partnering with companies such as BioImage will continue to enhance Definiens' leadership role in image analysis for the high-content screening market."

"Combining forces is the right way to meet today's demand of bringing together the best combination of technologies for leveraging the potential of high content cell-based assays" added Dr Patrik Dahlen, CEO of BioImage. "Our collaboration with Definiens significantly enhances our technological capabilities, and allows us to make image analysis an integral part of assay development. Cell-based screening will reach a new form of excellence by this joint effort. We are looking forward to make this collaboration a real success story in the future."

Commercial terms of the collaboration were not disclosed.

About BiImage

BiImage A/S is a drug discovery and assay services company focusing on cell-based pathway screening for the identification of new therapeutics. The Company has drug discovery projects in Inflammation and Oncology disease areas. BiImage's approach to drug discovery monitors protein translocation in living cells as the primary assay readout. BiImage tracks translocation of relevant targets that are tagged with Green Fluorescent Protein (GFP), and this is the basis of BiImage's unique Redistribution® assay platform. BiImage employs approximately 40 people at its research facility in Copenhagen, Denmark. The company has commercialized Redistribution® technology through companies such as Lilly, Merck, BMS and GE Healthcare. For more information please visit www.bioimage.com

About Definiens

Definiens is a leading provider of high-content image analysis solutions. Based on Definiens Cognition Network Technology®, a fundamental technology which models human thought, Definiens products enable the extraction of objects of interest from biomedical images. Main applications are in drug research and other biopharmaceutical processes. Definiens more than 100 customers in the field of life sciences are companies such as Altana, Aventis, Intervet, Merck, Novartis, and Novo Nordisk as well as Academia & Research Institutions such as NGFN and NIH. Founded in 1994 by Nobel Prize Laureate Prof. Dr. Gerd Binnig, Definiens today has 40 employees and is based in Munich, Germany. For further information regarding the company and its products please visit www.definiens.com

More Information:

Dr Patrik Dahlen
BiImage A/S
Moerkhoej Bygade 28,
2860 Soeborg, Denmark
Phone: +45 44 43 34 44
Fax: +45 44 43 75 05
Email: patrik.dahlen@bioimage.com

Andrea Müller-Beilschmidt
Definiens AG
Phone +49 (0)89 23 11 80-36
Mobile +49 (0)171 76 66 518
Fax +49 (0)89 23 11 80-90
Email: pr@definiens.com